Get started
Author

Frédéric Boisserie

Observed names: Boisserie, Frederic, F BOISSERIE, F. Boisserie, F., Boisserie, Frederic Boisserie
OpenAlex ID: A5090730919
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
2006 · Monica M. Bertagnolli, Craig J. Eagle, et al. · New England Journal of Medicine · 1,049
PDF
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
2014 · Shirish M Gadgeel, Leena Gandhi, et al. · The Lancet Oncology · 698
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
2023 · Shukui Qin, Masatoshi Kudo, et al. · JAMA Oncology · 264
PDF
RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
2019 · Shukui Qin, Richard S Finn, et al. · Future Oncology · 148
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
2016 · Ghassan K. Abou-Alfa, Oscar Puig, et al. · Journal of Hepatology · 137
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
2020 · Geoffrey I. Shapiro, Patricia LoRusso, et al. · British Journal of Cancer · 115
PDF
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
2022 · S. Qin, M. Kudo, et al. · Annals of Oncology · 66
PDF
Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats
1995 · Jean-Philippe Devillers, Frédéric Boisserie, et al. · Brain Research · 54
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
2017 · Ghassan K. Abou-Alfa, Chia-Jui Yen, et al. · Cancer Chemotherapy and Pharmacology · 31
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
2018 · Shukui Qin, Richard S. Finn, et al. · Journal of Clinical Oncology · 15
Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).
2016 · Oscar Puig, James Chih-Hsin Yang, et al. · Journal of Clinical Oncology · 12
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
2024 · Richard S. Finn, Masatoshi Kudo, et al. · Liver Cancer · 11
PDF
LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis
2022 · S. Qin, Y. Guo, et al. · Annals of Oncology · 6
A Phase 1 Study of Bet Inhibition Using Rg6146 in Relapsed/refractory (r/r) Myc‐expressing Diffuse Large B Cell Lymphoma (dlbcl)
2017 · P.F. Caimi, J.P. Eder, et al. · Hematological Oncology · 4
PDF
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
2023 · Richard S. Finn, Shukui Qin, et al. · Journal of Clinical Oncology · 2
Pain facilitory systems activated by opiate receptor stimulation: Possible role of NPFF, an anti-opioid peptide
1994 · G. Simonnet, J.-P. Devillers, et al. · Regulatory Peptides · 2
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
2015 · Rodrigo Dienstmann, Ulrik Lassen, et al. · Targeted Oncology · 1
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
2023 · Richard S. Finn, Shukui Qin, et al. · JCO Global Oncology
PDF
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
2023 · Arndt Vogel, Tim Meyer, et al. · Journal of Clinical Oncology
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
2023 · Masatoshi Kudo, Richard S. Finn, et al. · Journal of Clinical Oncology
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
2023 · A. Vogel, M. Kudo, et al. · Annals of Oncology
PDF
Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study
2023 · Masatoshi Kudo, Arndt Vogel, et al. · Journal of Hepatology
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study
2023 · Tim Meyer, Richard S. Finn, et al. · Journal of Hepatology
Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
2018 · S. Qin, R.S. Finn, et al. · Annals of Oncology
Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
2018 · S. Qin, R. Finn, et al. · Annals of Oncology
Works count: 29
Citation count: 2,612
H-index: 11
I10-index: 12
Year
Topic
Type